US3361742A
(en)
|
1964-12-07 |
1968-01-02 |
Hoffmann La Roche |
5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides
|
US3523941A
(en)
|
1967-03-06 |
1970-08-11 |
Hoffmann La Roche |
Benzodiazepine compounds and process for their preparation
|
US3524849A
(en)
|
1967-10-27 |
1970-08-18 |
Hoffmann La Roche |
Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein
|
JPS4843755B1
(fr)
|
1969-06-26 |
1973-12-20 |
|
|
FR2027356A1
(en)
|
1968-12-30 |
1970-09-25 |
Fujisawa Pharmaceutical Co |
Benzodiazepinone antibiotics
|
IL33558A
(en)
|
1968-12-30 |
1973-10-25 |
Fujisawa Pharmaceutical Co |
Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production
|
JPS6053033B2
(ja)
|
1976-12-28 |
1985-11-22 |
財団法人微生物化学研究会 |
新制癌抗生物質マゼスラマイシン及びその製造方法
|
JPS585916B2
(ja)
|
1977-12-27 |
1983-02-02 |
株式会社ミドリ十字 |
新規ベンゾジアゼピン系化合物
|
JPS5615289A
(en)
|
1979-07-17 |
1981-02-14 |
Green Cross Corp:The |
Novel benzodiazepinnbased compound 3
|
JPS57131791A
(en)
|
1980-12-31 |
1982-08-14 |
Fujisawa Pharmaceut Co Ltd |
Benzodiazepine derivative and its preparation
|
CA1173441A
(fr)
|
1981-02-27 |
1984-08-28 |
Hoffmann-La Roche Limited |
Imidazodiazepines
|
CA1185602A
(fr)
|
1981-02-27 |
1985-04-16 |
Emilio Kyburz |
Imidazodiazepines
|
CA1184175A
(fr)
|
1981-02-27 |
1985-03-19 |
Walter Hunkeler |
Imidazodiazepines
|
JPS58180487A
(ja)
|
1982-04-16 |
1983-10-21 |
Kyowa Hakko Kogyo Co Ltd |
抗生物質dc−81およびその製造法
|
US4427588A
(en)
|
1982-11-08 |
1984-01-24 |
Bristol-Myers Company |
Process for conversion of oxotomaymycin to tomaymycin
|
US4427587A
(en)
|
1982-11-10 |
1984-01-24 |
Bristol-Myers Company |
Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B
|
JPS59152329A
(ja)
|
1983-02-17 |
1984-08-31 |
Green Cross Corp:The |
局所障害抑制剤
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
FR2586683B1
(fr)
|
1985-08-29 |
1988-07-01 |
Centre Nat Rech Scient |
Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments
|
US5583024A
(en)
|
1985-12-02 |
1996-12-10 |
The Regents Of The University Of California |
Recombinant expression of Coleoptera luciferase
|
JP2660201B2
(ja)
|
1988-08-05 |
1997-10-08 |
塩野義製薬株式会社 |
新規ピロロ[1,4]ベンゾジアゼピン誘導体および老人性痴呆薬
|
CA2023779A1
(fr)
|
1989-08-23 |
1991-02-24 |
Margaret D. Moore |
Composes et methodes pour la detection et le traitement des infections a virus epstein-barr et des troubles de l'immunite
|
JPH053790A
(ja)
|
1990-04-19 |
1993-01-14 |
Fujisawa Pharmaceut Co Ltd |
デヒドロペプチダーゼ−i
|
US5256643A
(en)
|
1990-05-29 |
1993-10-26 |
The Government Of The United States |
Human cripto protein
|
WO1992007574A1
(fr)
|
1990-10-25 |
1992-05-14 |
Tanox Biosystems, Inc. |
Glycoproteines associees a des immunoglobulines a liaison membranaire et utilisees comme cibles anticorpales sur des cellules b
|
US5440021A
(en)
|
1991-03-29 |
1995-08-08 |
Chuntharapai; Anan |
Antibodies to human IL-8 type B receptor
|
US5543503A
(en)
|
1991-03-29 |
1996-08-06 |
Genentech Inc. |
Antibodies to human IL-8 type A receptor
|
DK0577752T4
(da)
|
1991-03-29 |
2007-10-22 |
Genentech Inc |
Human PF4A receptorer og deres anvendelse
|
FR2676230B1
(fr)
|
1991-05-07 |
1993-08-27 |
Centre Nat Rech Scient |
Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
|
JP3050424B2
(ja)
|
1991-07-12 |
2000-06-12 |
塩野義製薬株式会社 |
ヒトエンドセリンリセプター
|
US5264557A
(en)
|
1991-08-23 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Polypeptide of a human cripto-related gene, CR-3
|
US5362852A
(en)
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
US6153408A
(en)
|
1991-11-15 |
2000-11-28 |
Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
US6011146A
(en)
|
1991-11-15 |
2000-01-04 |
Institut Pasteur |
Altered major histocompatibility complex (MHC) determinant and methods of using the determinant
|
GB9205051D0
(en)
|
1992-03-09 |
1992-04-22 |
Cancer Res Campaign Tech |
Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
FR2696176B1
(fr)
|
1992-09-28 |
1994-11-10 |
Synthelabo |
Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
|
IL107366A
(en)
|
1992-10-23 |
2003-03-12 |
Chugai Pharmaceutical Co Ltd |
Genes coding for megakaryocyte potentiator
|
US5644033A
(en)
|
1992-12-22 |
1997-07-01 |
Health Research, Inc. |
Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
GB9316162D0
(en)
|
1993-08-04 |
1993-09-22 |
Zeneca Ltd |
Fungicides
|
US5773223A
(en)
|
1993-09-02 |
1998-06-30 |
Chiron Corporation |
Endothelin B1, (ETB1) receptor polypeptide and its encoding nucleic acid methods, and uses thereof
|
EP0647450A1
(fr)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Prodrogues améliorées pour activation médiée par enzyme
|
US5750370A
(en)
|
1995-06-06 |
1998-05-12 |
Human Genome Sciences, Inc. |
Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor
|
JPH08336393A
(ja)
|
1995-04-13 |
1996-12-24 |
Mitsubishi Chem Corp |
光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
|
US5707829A
(en)
|
1995-08-11 |
1998-01-13 |
Genetics Institute, Inc. |
DNA sequences and secreted proteins encoded thereby
|
US20020193567A1
(en)
|
1995-08-11 |
2002-12-19 |
Genetics Institute, Inc. |
Secreted proteins and polynucleotides encoding them
|
JP3646191B2
(ja)
|
1996-03-19 |
2005-05-11 |
大塚製薬株式会社 |
ヒト遺伝子
|
US6218519B1
(en)
|
1996-04-12 |
2001-04-17 |
Pro-Neuron, Inc. |
Compounds and methods for the selective treatment of cancer and bacterial infections
|
NZ332598A
(en)
|
1996-05-17 |
2000-04-28 |
Schering Corp |
Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
|
EP0961619A4
(fr)
|
1996-09-27 |
2001-09-26 |
Bristol Myers Squibb Co |
Promedicaments hydrolysables pour la liberation de medicaments anticancereux dans des cellules metastatiques
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
US5945511A
(en)
|
1997-02-20 |
1999-08-31 |
Zymogenetics, Inc. |
Class II cytokine receptor
|
US20030185830A1
(en)
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US7033827B2
(en)
|
1997-02-25 |
2006-04-25 |
Corixa Corporation |
Prostate-specific polynucleotide compositions
|
US6261791B1
(en)
|
1997-03-10 |
2001-07-17 |
The Regents Of The University Of California |
Method for diagnosing cancer using specific PSCA antibodies
|
CA2281877C
(fr)
|
1997-03-10 |
2010-01-05 |
The Regents Of The University Of California |
Antigene de cellule souche prostatique (psca)
|
US6541212B2
(en)
|
1997-03-10 |
2003-04-01 |
The Regents Of The University Of California |
Methods for detecting prostate stem cell antigen protein
|
US6555339B1
(en)
|
1997-04-14 |
2003-04-29 |
Arena Pharmaceuticals, Inc. |
Non-endogenous, constitutively activated human protein-coupled receptors
|
US6319688B1
(en)
|
1997-04-28 |
2001-11-20 |
Smithkline Beecham Corporation |
Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
|
WO1998051824A1
(fr)
|
1997-05-15 |
1998-11-19 |
Abbott Laboratories |
Reactifs et procedes utiles au depistage de maladies du tractus urinaire
|
US6890749B2
(en)
|
1997-05-15 |
2005-05-10 |
Abbott Laboratories |
Reagents and methods useful for detecting diseases of the prostate
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
US20030060612A1
(en)
|
1997-10-28 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20020034749A1
(en)
|
1997-11-18 |
2002-03-21 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6110695A
(en)
|
1997-12-02 |
2000-08-29 |
The Regents Of The University Of California |
Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
|
WO2004031238A2
(fr)
|
2002-10-03 |
2004-04-15 |
Mcgill Univeristy |
Agents de liaison d'antigenes carcinoembryonnaires (cea) permettant d'inverser les effets tumorigenes a mediation cea sur des cellules cancereuses humaines et leurs utilisations
|
JP4603157B2
(ja)
|
1998-03-13 |
2010-12-22 |
ザ バーナム インスティチュート |
種々の選択された器官または組織にホーミングする分子
|
CA2331846C
(fr)
|
1998-05-13 |
2010-01-12 |
Epimmune Inc. |
Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation
|
US20030064397A1
(en)
|
1998-05-22 |
2003-04-03 |
Incyte Genomics, Inc. |
Transmembrane protein differentially expressed in prostate and lung tumors
|
US6835807B1
(en)
|
1998-05-22 |
2004-12-28 |
Daiichi Pharmaceuticals Co., Ltd. |
Drug complex and drug delivery system
|
US20020187472A1
(en)
|
2001-03-09 |
2002-12-12 |
Preeti Lal |
Steap-related protein
|
AU5094699A
(en)
|
1998-07-08 |
2000-02-01 |
E-Ink Corporation |
Methods for achieving improved color in microencapsulated electrophoretic devices
|
GB9818732D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collection of compounds
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
GB9818730D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Collections of compounds
|
WO2000012130A1
(fr)
|
1998-08-27 |
2000-03-09 |
Smithkline Beecham Corporation |
Agonistes et antagonistes de rp105
|
ATE240334T1
(de)
|
1998-08-27 |
2003-05-15 |
Spirogen Ltd |
Pyrrolobenzodiazepine
|
JP4689781B2
(ja)
|
1998-09-03 |
2011-05-25 |
独立行政法人科学技術振興機構 |
アミノ酸輸送蛋白及びその遺伝子
|
AU5963699A
(en)
|
1998-10-02 |
2000-04-26 |
Mcmaster University |
Spliced form of (erb)b-2/neu oncogene
|
WO2001057188A2
(fr)
|
2000-02-03 |
2001-08-09 |
Hyseq, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US6858710B2
(en)
|
1998-12-17 |
2005-02-22 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6962980B2
(en)
|
1999-09-24 |
2005-11-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6468546B1
(en)
|
1998-12-17 |
2002-10-22 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of ovarian cancer
|
US20030091580A1
(en)
|
2001-06-18 |
2003-05-15 |
Mitcham Jennifer L. |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
DE69939553D1
(de)
|
1998-12-30 |
2008-10-23 |
Beth Israel Hospital |
Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
|
CZ20012587A3
(cs)
|
1999-01-29 |
2002-05-15 |
Corixa Corporation |
Izolovaný protein, nukleová kyselina, virový vektor, farmaceutický prostředek, izolovaná populace T buněk, způsob posílení imunitní odpovědi, způsob odstranění nádorových buněk, způsob stimulace a/nebo namnoľení T buněk a způsob přípravy fúzního proteinu
|
GB9905124D0
(en)
|
1999-03-05 |
1999-04-28 |
Smithkline Beecham Biolog |
Novel compounds
|
US7232889B2
(en)
|
1999-03-08 |
2007-06-19 |
Genentech, Inc. |
PRO300 antibodies
|
AU3395900A
(en)
|
1999-03-12 |
2000-10-04 |
Human Genome Sciences, Inc. |
Human lung cancer associated gene sequences and polypeptides
|
US7312303B2
(en)
|
1999-05-11 |
2007-12-25 |
Genentech, Inc. |
Anti-PRO4980 antibodies
|
US6268488B1
(en)
|
1999-05-25 |
2001-07-31 |
Barbas, Iii Carlos F. |
Prodrug activation using catalytic antibodies
|
CA2370466C
(fr)
|
1999-06-25 |
2011-02-08 |
Sharon Erickson |
Techniques de traitement utilisant des conjugues maytansinoides-anticorps anti-erbb
|
WO2000075655A1
(fr)
|
1999-06-03 |
2000-12-14 |
Takeda Chemical Industries, Ltd. |
Procede de criblage avec cd100
|
US6302318B1
(en)
|
1999-06-29 |
2001-10-16 |
General Electric Company |
Method of providing wear-resistant coatings, and related articles
|
US20030119113A1
(en)
|
1999-07-20 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7297770B2
(en)
|
1999-08-10 |
2007-11-20 |
Genentech, Inc. |
PRO6496 polypeptides
|
US7294696B2
(en)
|
1999-08-17 |
2007-11-13 |
Genentech Inc. |
PRO7168 polypeptides
|
US6909006B1
(en)
|
1999-08-27 |
2005-06-21 |
Spirogen Limited |
Cyclopropylindole derivatives
|
CA2380355A1
(fr)
|
1999-09-01 |
2001-03-08 |
Genentech, Inc. |
Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
|
US20030129192A1
(en)
|
1999-09-10 |
2003-07-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030232056A1
(en)
|
1999-09-10 |
2003-12-18 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US20030206918A1
(en)
|
1999-09-10 |
2003-11-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
ES2309012T3
(es)
|
1999-10-29 |
2008-12-16 |
Genentech, Inc. |
Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
|
EP2316843B1
(fr)
|
1999-11-29 |
2015-10-14 |
The Trustees of Columbia University in the City of New York |
Isolation de cinq nouveaux gènes codant pour le mélanome de type récepteur Fc impliqué dans la pathogenèse du lymphome-mélanome
|
CA2392510A1
(fr)
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
|
CA2393738A1
(fr)
|
1999-12-10 |
2001-06-14 |
Epimmune Inc. |
Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
|
NZ502058A
(en)
|
1999-12-23 |
2003-11-28 |
Ovita Ltd |
Isolated mutated nucleic acid molecule for regulation of ovulation rate
|
ATE459369T1
(de)
|
1999-12-23 |
2010-03-15 |
Zymogenetics Inc |
Verfahren zur behandlung von entzündungen
|
ATE485306T1
(de)
|
1999-12-23 |
2010-11-15 |
Zymogenetics Inc |
Löslicher interleukin-20-rezeptor
|
US6610286B2
(en)
|
1999-12-23 |
2003-08-26 |
Zymogenetics, Inc. |
Method for treating inflammation using soluble receptors to interleukin-20
|
ATE422369T1
(de)
|
1999-12-24 |
2009-02-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur verlängerung der entsorgungshalbwertszeit von biowirksamen verbindungen
|
US20040001827A1
(en)
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
US7294695B2
(en)
|
2000-01-20 |
2007-11-13 |
Genentech, Inc. |
PRO10268 polypeptides
|
WO2001053463A2
(fr)
|
2000-01-21 |
2001-07-26 |
Corixa Corporation |
COMPOSES ET PROCEDES DE PREVENTION ET DE TRAITEMENT DE MALIGNITES ASSOCIEES A HER-2/neu
|
US20030224379A1
(en)
|
2000-01-21 |
2003-12-04 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
US20030104562A1
(en)
|
2000-02-11 |
2003-06-05 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
AU2001238596A1
(en)
|
2000-02-22 |
2001-09-03 |
Millennium Pharmaceuticals, Inc. |
18607, a novel human calcium channel
|
US20030219806A1
(en)
|
2000-02-22 |
2003-11-27 |
Millennium Pharmaceuticals, Inc. |
Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses therefor
|
US20040052793A1
(en)
|
2001-02-22 |
2004-03-18 |
Carter Paul J. |
Caspase activivated prodrugs therapy
|
US20040005561A1
(en)
|
2000-03-01 |
2004-01-08 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU2001245280A1
(en)
|
2000-03-07 |
2001-09-17 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
WO2002088170A2
(fr)
|
2001-04-26 |
2002-11-07 |
Biogen, Inc. |
Anticorps de blocage cripto et utilisations correspondantes
|
AU4941101A
(en)
|
2000-03-24 |
2001-10-08 |
Fahri Saatcioglu |
Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
|
AU2001250412A1
(en)
|
2000-03-31 |
2001-10-08 |
Ipf Pharmaceuticals Gmbh |
Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
|
AU2001253140A1
(en)
|
2000-04-03 |
2001-10-15 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Tumor markers in ovarian cancer
|
CA2402392A1
(fr)
|
2000-04-07 |
2001-10-18 |
Arena Pharmaceuticals, Inc. |
Recepteurs connus couples a la proteine g non endogenes a activation constitutive
|
WO2001088133A2
(fr)
|
2000-05-18 |
2001-11-22 |
Lexicon Genetics Incorporated |
Nouveaux homologues humains de semaphorine et polynucleotides codant ceux-ci
|
AU2001274888A1
(en)
|
2000-05-19 |
2001-12-03 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
WO2001094641A2
(fr)
|
2000-06-09 |
2001-12-13 |
Idec Pharmaceuticals Corporation |
Nouvelles cibles geniques et ligands se fixant a celles-ci pour le traitement et le diagnostic de carcinomes ovariens
|
AU2001268471A1
(en)
|
2000-06-16 |
2002-01-02 |
Incyte Genomics, Inc. |
G-protein coupled receptors
|
CA2413186A1
(fr)
|
2000-06-30 |
2002-01-10 |
Incyte Genomics, Inc. |
Molecules de matrice extracellulaire et d'adhesion cellulaire
|
CA2406649A1
(fr)
|
2000-06-30 |
2002-01-10 |
Human Genome Sciences, Inc. |
Polynucleotides du type b7, polypeptides et anticorps en rapport
|
AU2001273194A1
(en)
|
2000-06-30 |
2002-01-14 |
Amgen Inc. |
B7-Like Molecules and Uses Thereof
|
AU2002214531A1
(en)
|
2000-07-03 |
2002-01-30 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040044179A1
(en)
|
2000-07-25 |
2004-03-04 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6891030B2
(en)
|
2000-07-27 |
2005-05-10 |
Mayo Foundation For Medical Education And Research |
T-cell immunoregulatory molecule
|
WO2002010382A2
(fr)
|
2000-07-28 |
2002-02-07 |
Ulrich Wissenbach |
Marqueurs trp8, trp9 et trp10 associes au cancer
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
IL154415A0
(en)
|
2000-08-14 |
2003-09-17 |
Corixa Corp |
Polynucleotides that encode her-2/neu polypeptides and pharmaceutical compositions containing the same
|
WO2002013847A2
(fr)
|
2000-08-14 |
2002-02-21 |
Corixa Corporation |
Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
|
CA2420140A1
(fr)
|
2000-08-24 |
2002-02-28 |
Genentech, Inc. |
Compositions et procedes de diagnostic et traitement de tumeurs
|
GB0020953D0
(en)
|
2000-08-24 |
2000-10-11 |
Smithkline Beecham Biolog |
Vaccine
|
AU2001290548A1
(en)
|
2000-09-11 |
2002-03-26 |
Hyseq, Inc. |
Novel nucleic acids and polypeptides
|
US7491797B2
(en)
|
2000-09-15 |
2009-02-17 |
Genentech, Inc. |
PRO6308 polypeptide
|
US6613567B1
(en)
|
2000-09-15 |
2003-09-02 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of Her-2 expression
|
JP4908723B2
(ja)
|
2000-09-15 |
2012-04-04 |
ザイモジェネティクス, インコーポレイテッド |
炎症を治療するための方法
|
EP1320604A2
(fr)
|
2000-09-18 |
2003-06-25 |
Biogen, Inc. |
Mutant cripto et utilisations de ce dernier
|
UA83458C2
(uk)
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
DK1320522T3
(da)
|
2000-09-19 |
2006-04-03 |
Moses Lee |
Achirale analoger af CC-1065 og af duocarmyciner samt præparater og metoder til anvendelse deraf
|
WO2002030268A2
(fr)
|
2000-10-13 |
2002-04-18 |
Eos Biotechnology, Inc. |
Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
|
ES2329012T3
(es)
|
2000-11-07 |
2009-11-20 |
Zymogenetics, Inc. |
Receptor del factor de necrosis tumoral humano.
|
US20020150573A1
(en)
|
2000-11-10 |
2002-10-17 |
The Rockefeller University |
Anti-Igalpha-Igbeta antibody for lymphoma therapy
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
WO2002061087A2
(fr)
|
2000-12-19 |
2002-08-08 |
Lifespan Biosciences, Inc. |
Peptides antigeniques destines a des recepteurs couples a la proteine g (gpcr), anticorps s'y rapportant, et systeme d'identification desdits peptides antigeniques
|
AU2002243495A1
(en)
|
2001-01-12 |
2002-07-24 |
University Of Medicine And Dentistry Of New Jersey |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
US20030119119A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030119126A1
(en)
|
2001-01-16 |
2003-06-26 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
WO2002059377A2
(fr)
|
2001-01-24 |
2002-08-01 |
Protein Design Labs |
Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
|
WO2002060317A2
(fr)
|
2001-01-30 |
2002-08-08 |
Corixa Corporation |
Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
|
WO2002064798A1
(fr)
|
2001-02-12 |
2002-08-22 |
Bionomics Limited |
Sequences d'adn exprimees de façon differentielle dans des lignees cellulaires tumorales
|
WO2002071928A2
(fr)
|
2001-03-14 |
2002-09-19 |
Millennium Pharmaceuticals, Inc. |
Molecules d'acide nucleique et proteines destinees a l'identification, l'evaluation, la prevention et la therapie du cancer des ovaires
|
EP1243276A1
(fr)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Prodrogues activables à séparateurs allongés et multiples
|
AU2002311787A1
(en)
|
2001-03-28 |
2002-10-15 |
Zycos Inc. |
Translational profiling
|
US6362331B1
(en)
|
2001-03-30 |
2002-03-26 |
Council Of Scientific And Industrial Research |
Process for the preparation of antitumor agents
|
WO2003008537A2
(fr)
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Sequences d'epitope
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
MXPA03009510A
(es)
|
2001-04-17 |
2005-04-29 |
Univ Arkansas |
Secuencias de repeticion del gen ca125 y su uso para intervenciones de diagnosticos y terapeuticas.
|
AU2002309583A1
(en)
|
2001-04-18 |
2002-11-05 |
Protein Desing Labs, Inc. |
Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
CA2446788A1
(fr)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
|
US20030078399A1
(en)
|
2001-05-11 |
2003-04-24 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
|
CA2448123C
(fr)
|
2001-05-24 |
2012-09-11 |
Zymogenetics, Inc. |
Proteines hybrides taci-immunoglobuline
|
US7157558B2
(en)
|
2001-06-01 |
2007-01-02 |
Genentech, Inc. |
Polypeptide encoded by a polynucleotide overexpresses in tumors
|
WO2002098358A2
(fr)
|
2001-06-04 |
2002-12-12 |
Eos Biotechnology, Inc. |
Procedes de diagnostic et de traitement du cancer prostatique androgene-dependant, cancer prostatique subissant un retrait d'androgenes et cancer prostatique androgene-independant
|
JP2005518185A
(ja)
|
2001-06-04 |
2005-06-23 |
キュラジェン コーポレイション |
新規タンパク質およびそれをコード化する核酸
|
JP2004528043A
(ja)
|
2001-06-05 |
2004-09-16 |
エクセリクシス・インコーポレイテッド |
p53経路のモディファイヤーとしてのCHDsおよび使用方法
|
DE60237917D1
(de)
|
2001-06-05 |
2010-11-18 |
Exelixis Inc |
Gfats als modifikatoren des p53-wegs und verwendungsverfahren
|
US7235358B2
(en)
|
2001-06-08 |
2007-06-26 |
Expression Diagnostics, Inc. |
Methods and compositions for diagnosing and monitoring transplant rejection
|
US7125663B2
(en)
|
2001-06-13 |
2006-10-24 |
Millenium Pharmaceuticals, Inc. |
Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
|
US7189507B2
(en)
|
2001-06-18 |
2007-03-13 |
Pdl Biopharma, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
CA2451465A1
(fr)
|
2001-06-18 |
2002-12-27 |
Eos Biotechnology Inc. |
Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
|
AU2002322280A1
(en)
|
2001-06-21 |
2003-01-21 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
WO2003002717A2
(fr)
|
2001-06-28 |
2003-01-09 |
Schering Corporation |
Activite biologique de ak155
|
WO2003004529A2
(fr)
|
2001-07-02 |
2003-01-16 |
Licentia Ltd. |
Materiaux de recepteur ephrine-tie et leurs procedes
|
US20040076955A1
(en)
|
2001-07-03 |
2004-04-22 |
Eos Biotechnology, Inc. |
Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
|
WO2003003984A2
(fr)
|
2001-07-05 |
2003-01-16 |
Curagen Corporation |
Nouvelles proteines et nouveaux acides nucleiques codant ces proteines
|
US7446185B2
(en)
|
2001-07-18 |
2008-11-04 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
WO2003009814A2
(fr)
|
2001-07-25 |
2003-02-06 |
Millennium Pharmaceuticals, Inc. |
Nouveaux genes, compositions, trousses et methodes d'identification, evaluation, prevention, et traitement du cancer de la prostate
|
HUP0500992A3
(en)
|
2001-08-03 |
2007-11-28 |
Genentech Inc |
Tacis and br3 polypeptides and uses thereof
|
WO2003016475A2
(fr)
|
2001-08-14 |
2003-02-27 |
The General Hospital Corporation |
Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur
|
US20030092013A1
(en)
|
2001-08-16 |
2003-05-15 |
Vitivity, Inc. |
Diagnosis and treatment of vascular disease
|
AU2002313559A1
(en)
|
2001-08-23 |
2003-03-10 |
Oxford Biomedica (Uk) Limited |
Genes
|
US6902930B2
(en)
|
2001-08-29 |
2005-06-07 |
Vanderbilt University |
Human Mob-5 (IL-24) receptors and uses thereof
|
US20030124579A1
(en)
|
2001-09-05 |
2003-07-03 |
Eos Biotechnology, Inc. |
Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
|
CA2459318C
(fr)
|
2001-09-06 |
2017-09-26 |
Agensys, Inc. |
Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer
|
JP2005518782A
(ja)
|
2001-09-17 |
2005-06-30 |
プロテイン デザイン ラブス, インコーポレイテッド |
ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
|
ATE486092T1
(de)
|
2001-09-18 |
2010-11-15 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
US20050004017A1
(en)
|
2001-09-18 |
2005-01-06 |
Yuval Reiss |
Methods and compositions for treating hcap associated diseases
|
CA2460621A1
(fr)
|
2001-09-19 |
2003-03-27 |
Nuvelo, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
WO2003026577A2
(fr)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-aminobenzyl ether dans des agents d'administration de medicaments
|
AU2002327792A1
(en)
|
2001-09-28 |
2003-04-07 |
Bing Yang |
Diagnosis and treatment of diseases caused by mutations in cd72
|
US20050130117A1
(en)
|
2001-10-03 |
2005-06-16 |
Davis Cong L. |
Modulators of lymphocyte activation and migration
|
WO2003029421A2
(fr)
|
2001-10-03 |
2003-04-10 |
Origene Technologies, Inc. |
Genes regules du cancer du sein
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2842429A1
(fr)
|
2001-10-19 |
2003-05-01 |
Genentech, Inc. |
Compositions et procedes pour le diagnostic et le traitement d'affections intestinales inflammatoires
|
US7825089B2
(en)
|
2001-10-24 |
2010-11-02 |
National Jewish Health |
Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto
|
BR0213738A
(pt)
|
2001-10-31 |
2006-11-21 |
Alcon Inc |
proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma
|
WO2003042661A2
(fr)
|
2001-11-13 |
2003-05-22 |
Protein Design Labs, Inc. |
Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
|
US20030232350A1
(en)
|
2001-11-13 |
2003-12-18 |
Eos Biotechnology, Inc. |
Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
|
WO2003043583A2
(fr)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Traitement des troubles immunologiques au moyen des anticorps anti-cd30
|
US7344843B2
(en)
|
2001-11-29 |
2008-03-18 |
Serono Genetics Institute S.A. |
Agonists and antagonists of prolixin for the treatment of metabolic disorders
|
WO2003048321A2
(fr)
*
|
2001-12-03 |
2003-06-12 |
Alexion Pharmaceuticals, Inc. |
Anticorps hybrides
|
AU2002349784A1
(en)
|
2001-12-03 |
2003-06-17 |
Asahi Kasei Pharma Corporation |
Nf-kappab activating genes
|
WO2003054152A2
(fr)
|
2001-12-10 |
2003-07-03 |
Nuvelo, Inc. |
Nouveaux acides nucleiques et polypeptides
|
US20030134790A1
(en)
|
2002-01-11 |
2003-07-17 |
University Of Medicine And Dentistry Of New Jersey |
Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
|
CA2473549C
(fr)
|
2002-01-16 |
2011-02-15 |
Japan Science And Technology Agency |
Dispositif de reproduction holographique d'images mobiles et dispositif de reproduction holographique d'images mobiles couleur
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
EP1476120B1
(fr)
|
2002-02-21 |
2010-09-29 |
Duke University |
Methodes therapeutiques utilisant des anticorps anti-cd22
|
CA2476518A1
(fr)
|
2002-02-22 |
2003-09-04 |
Genentech, Inc. |
Compositions et methodes de traitement de maladies relatives au systeme immunitaire
|
US20030219795A1
(en)
|
2002-03-01 |
2003-11-27 |
Marcia Belvin |
SCDs as modifiers of the p53 pathway and methods of use
|
US20050287147A1
(en)
|
2002-05-15 |
2005-12-29 |
Reinhard Ebner |
Cancer-linked gene as target for chemotherapy
|
US6660856B2
(en)
|
2002-03-08 |
2003-12-09 |
Kaohsiung Medical University |
Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues
|
EP2258712A3
(fr)
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
|
CA2486490A1
(fr)
|
2002-03-19 |
2003-12-31 |
Curagen Corporation |
Polypeptides therapeutiques, acides nucleiques les codant et principes d'utilisation
|
JP2005534286A
(ja)
|
2002-03-21 |
2005-11-17 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
キナーゼインヒビターの同定
|
JP2005520566A
(ja)
|
2002-03-22 |
2005-07-14 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
Cripto特異的抗体
|
US7193069B2
(en)
|
2002-03-22 |
2007-03-20 |
Research Association For Biotechnology |
Full-length cDNA
|
JP2005521429A
(ja)
|
2002-03-25 |
2005-07-21 |
ユーエービー リサーチ ファウンデーション |
Fcレセプターホモログ、試薬およびこれらの使用
|
AU2003222103A1
(en)
|
2002-03-28 |
2003-10-13 |
Idec Pharmaceuticals Corporation |
Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
|
US20030194704A1
(en)
|
2002-04-03 |
2003-10-16 |
Penn Sharron Gaynor |
Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
|
BR0308953A
(pt)
|
2002-04-05 |
2006-03-14 |
Agensys Inc |
composições, proteìna, polinucleotìdeo, método de geração de uma resposta imune, método de detecção, composição farmacêutica, anticorpo ou seu fragmento, animal transgênico, hibridoma, método de fornecimento de um agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas
|
WO2003087768A2
(fr)
|
2002-04-12 |
2003-10-23 |
Mitokor |
Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
|
CA2481507A1
(fr)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
|
US20030224467A1
(en)
|
2002-04-17 |
2003-12-04 |
Osborne C. Kent |
AIB1 as a prognostic marker and predictor of resistance to endocrine therapy
|
WO2003093444A2
(fr)
|
2002-05-03 |
2003-11-13 |
Incyte Corporation |
Transporteurs et canaux ioniques
|
US20030224454A1
(en)
|
2002-05-30 |
2003-12-04 |
Ryseck Rolf Peter |
Human solute carrier family 7, member 11 (hSLC7A11)
|
EP1575492A4
(fr)
|
2002-06-04 |
2007-05-09 |
Avalon Pharmaceuticals |
Gene lie au cancer comme cible de chimiotherapie
|
AU2003240495A1
(en)
|
2002-06-04 |
2003-12-19 |
Incyte Corporation |
Diagnostics markers for lung cancer
|
EP2275544A3
(fr)
|
2002-06-06 |
2011-03-30 |
Oncotherapy Science, Inc. |
Gènes et polypeptides en rapport avec les cancers du colon chez l'homme
|
WO2003104270A2
(fr)
|
2002-06-06 |
2003-12-18 |
Ingenium Pharmaceuticals Ag |
Genes de la duduline 2, produits d'expression, modele animal non humain : utilisations dans les maladies hematologiques humaines
|
AU2003249691A1
(en)
|
2002-06-07 |
2003-12-22 |
Avalon Pharmaceuticals, Inc |
Cancer-linked gene as target for chemotherapy
|
AU2003245441A1
(en)
|
2002-06-12 |
2003-12-31 |
Avalon Pharmaceuticals, Inc. |
Cancer-linked gene as target for chemotherapy
|
AU2003247576A1
(en)
|
2002-06-18 |
2003-12-31 |
Archemix Corp. |
Aptamer-toxin molecules and methods for using same
|
US20040249130A1
(en)
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
CA2489803A1
(fr)
|
2002-06-20 |
2003-12-31 |
The Regents Of The University Of California |
Compositions et procedes de modulation de l'activite lymphocytaire
|
US20060275287A1
(en)
|
2002-06-21 |
2006-12-07 |
Brad St Croix |
Scroll compressor
|
DE10229834A1
(de)
|
2002-07-03 |
2004-01-29 |
Zinser Textilmaschinen Gmbh |
Streckwerk für Spinnmaschinen mit nachgeordneter Verdichtungsvorrichtung
|
AU2003281515A1
(en)
|
2002-07-19 |
2004-02-09 |
Cellzome Ag |
Protein complexes of cellular networks underlying the development of cancer and other diseases
|
NZ537781A
(en)
|
2002-07-25 |
2008-04-30 |
Genentech Inc |
Taci antibodies and uses thereof
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
JP4741838B2
(ja)
|
2002-07-31 |
2011-08-10 |
シアトル ジェネティクス,インコーポレーテッド |
癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
|
JP2004121218A
(ja)
|
2002-08-06 |
2004-04-22 |
Jenokkusu Soyaku Kenkyusho:Kk |
気管支喘息または慢性閉塞性肺疾患の検査方法
|
WO2004015426A1
(fr)
|
2002-08-06 |
2004-02-19 |
Bayer Healthcare Ag |
Agents diagnostiques et therapeutiques contre des maladies associees au recepteur 5 de la chemokine cxc humain (cxcr5)
|
EP1578371A4
(fr)
|
2002-08-19 |
2009-05-20 |
Genentech Inc |
Compositions et methodes de diagnostic et de traitement des tumeurs
|
WO2004020583A2
(fr)
|
2002-08-27 |
2004-03-11 |
Bristol-Myers Squibb Company |
Identification de polynucleotides pour predire l'activite de composes interagissant avec et/ou modulant des proteines tyrosine kinases et/ou des voies de proteines tyrosine kinases dans des cellules mammaires
|
WO2004020595A2
(fr)
|
2002-08-29 |
2004-03-11 |
Five Prime Therapeutics, Inc. |
Nouveaux polypeptides humains codes par des polynucleotides
|
AU2003256038A1
(en)
|
2002-08-30 |
2004-03-19 |
Ramot At Tel Aviv University Ltd. |
Self-immolative dendrimers releasing many active moieties upon a single activating event
|
AU2002951346A0
(en)
|
2002-09-05 |
2002-09-26 |
Garvan Institute Of Medical Research |
Diagnosis of ovarian cancer
|
CA2496888A1
(fr)
|
2002-09-06 |
2004-03-18 |
Mannkind Corporation |
Sequences de sites antigeniques
|
JP2006513702A
(ja)
|
2002-09-09 |
2006-04-27 |
ヌラ インコーポレーティッド |
Gタンパク質共役受容体およびその使用
|
JP2004113151A
(ja)
|
2002-09-27 |
2004-04-15 |
Sankyo Co Ltd |
癌遺伝子及びその用途
|
CA2501131A1
(fr)
|
2002-10-04 |
2004-04-22 |
Van Andel Research Institute |
Sous classification moleculaire de tumeurs renales et decouverte de nouveaux marqueurs diagnostiques
|
US20040138269A1
(en)
|
2002-10-11 |
2004-07-15 |
Sugen, Inc. |
Substituted pyrroles as kinase inhibitors
|
CA2503748A1
(fr)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions et procedes de traitement des maladies liees aux cellules k naturelles
|
CA2503621A1
(fr)
|
2002-11-13 |
2004-05-27 |
Genentech, Inc. |
Procedes et compositions pour diagnostiquer une dysplasie
|
GB0226593D0
(en)
|
2002-11-14 |
2002-12-24 |
Consultants Ltd |
Compounds
|
EP1560599A1
(fr)
|
2002-11-14 |
2005-08-10 |
Syntarga B.V. |
Promedicaments con us en tant qu'espaceurs de liberation multiple a elimination automatique
|
EP1578372A4
(fr)
|
2002-11-15 |
2007-10-17 |
Univ Arkansas |
Gene ca125 et utilisation de celui-ci aux fins d'interventions diagnostiques et therapeutiques
|
ES2392511T3
(es)
|
2002-11-15 |
2012-12-11 |
Musc Foundation For Research Development |
Moduladores de complemento dianas sobre el receptor 2 de complemento
|
US20080213166A1
(en)
|
2002-11-20 |
2008-09-04 |
Biogen Idec Inc. |
Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
|
CA2507044A1
(fr)
|
2002-11-21 |
2004-06-10 |
Mary Lucero |
Modulation purinergique d'odeur
|
WO2004048938A2
(fr)
|
2002-11-26 |
2004-06-10 |
Protein Design Labs, Inc. |
Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
|
US20070154886A1
(en)
|
2002-12-06 |
2007-07-05 |
Macina Roberto A |
Composition, splice variants and methods relating to ovarian specific genes and proteins
|
US20040157278A1
(en)
|
2002-12-13 |
2004-08-12 |
Bayer Corporation |
Detection methods using TIMP 1
|
ES2388280T3
(es)
|
2002-12-20 |
2012-10-11 |
Abbott Biotherapeutics Corp. |
Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
|
US20050249671A9
(en)
|
2002-12-23 |
2005-11-10 |
David Parmelee |
Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
|
WO2004063709A2
(fr)
|
2003-01-08 |
2004-07-29 |
Bristol-Myers Squibb Company |
Biomarqueurs et methodes de determination d'une sensibilite aux modulateurs du facteur de croissance epidermique
|
US20050227301A1
(en)
|
2003-01-10 |
2005-10-13 |
Polgen |
Cell cycle progression proteins
|
US20050181375A1
(en)
|
2003-01-10 |
2005-08-18 |
Natasha Aziz |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
|
US20040171823A1
(en)
|
2003-01-14 |
2004-09-02 |
Nadler Steven G. |
Polynucleotides and polypeptides associated with the NF-kappaB pathway
|
JP2007520996A
(ja)
|
2003-01-15 |
2007-08-02 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
44390、54181、211、5687、884、1405、636、4421、5410、30905、2045、16405、18560、2047、33751、52872、14063、20739、32544、43239、44373、51164、53010、16852、1587、2207、22245、2387、52908、69112、14990、18547、115、579、15985、15625、760、18603、2395、2554、8675、32720、4809、14303、16816、17827、32620、577、619、1423、2158、8263、15402、16209、16386、21165、30911、41897、1643、2543、9626、13231、32409、84260、2882、8203、32678または55053を用いて泌尿器科障害を処置するための方法および組成物
|
US20060228710A1
(en)
|
2003-02-14 |
2006-10-12 |
Morris David W |
Novel therapeutic targets in cancer
|
US20030224411A1
(en)
|
2003-03-13 |
2003-12-04 |
Stanton Lawrence W. |
Genes that are up- or down-regulated during differentiation of human embryonic stem cells
|
DE60326060D1
(de)
|
2003-03-31 |
2009-03-19 |
Council Scient Ind Res |
Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
AU2004284075A1
(en)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
GB0416511D0
(en)
|
2003-10-22 |
2004-08-25 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
PT2489364E
(pt)
|
2003-11-06 |
2015-04-16 |
Seattle Genetics Inc |
Compostos de monometilvalina conjugados com anticorpos
|
US20050288491A1
(en)
|
2004-02-17 |
2005-12-29 |
Wilson David S |
Super-humanized antibodies against respiratory syncytial virus
|
US7375078B2
(en)
|
2004-02-23 |
2008-05-20 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
AU2005219626B2
(en)
|
2004-03-01 |
2010-11-18 |
Medimmune Limited |
11-hydroxy-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines
|
GB0404578D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
GB0404574D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Amino acids
|
DE102004010943A1
(de)
|
2004-03-03 |
2005-09-29 |
Degussa Ag |
Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten
|
JP5166861B2
(ja)
|
2004-03-09 |
2013-03-21 |
スピロゲン リミティッド |
ピロロベンゾジアゼピン
|
FR2869231B1
(fr)
|
2004-04-27 |
2008-03-14 |
Sod Conseils Rech Applic |
Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
|
GB0410725D0
(en)
|
2004-05-13 |
2004-06-16 |
Spirogen Ltd |
Pyrrolobenzodiazepine therapeutic agents
|
DK1791565T3
(en)
|
2004-09-23 |
2016-08-01 |
Genentech Inc |
Cysteingensplejsede antibodies and conjugates
|
WO2006068325A2
(fr)
|
2004-12-24 |
2006-06-29 |
Showa Denko K. K. |
Procede de fabrication d'alliage semiconducteur thermoelectrique, module de conversion thermoelectrique et generateur de courant thermoelectrique
|
CN101115771B
(zh)
|
2005-02-03 |
2013-06-05 |
安迪拓普有限公司 |
人类抗体和蛋白质
|
EP1871418B1
(fr)
|
2005-04-19 |
2014-03-19 |
Seattle Genetics, Inc. |
Agents de liaison anti-cd70 humanises et utilisations
|
DK1879901T3
(da)
|
2005-04-21 |
2010-05-03 |
Spirogen Ltd |
Pyrrolobenzodiazepiner
|
ATE427949T1
(de)
|
2005-10-05 |
2009-04-15 |
Spirogen Ltd |
4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
|
CN109053523B
(zh)
|
2005-10-07 |
2022-03-25 |
埃克塞利希斯股份有限公司 |
作为用于治疗增生性疾病的mek抑制剂的吖丁啶
|
EA016429B1
(ru)
*
|
2005-12-30 |
2012-04-30 |
Мерк Патент Гмбх |
Антитела против cd19 с пониженной иммуногенностью
|
EP1813614B1
(fr)
|
2006-01-25 |
2011-10-05 |
Sanofi |
Agents cytotoxiques comprenant de nouveaux dérivés de Tomaymycine
|
ZA200900545B
(en)
|
2006-07-18 |
2010-03-31 |
Sanofi Aventis |
Antagonist antibody against EPHA2 for the treatment of cancer
|
PL2383297T3
(pl)
*
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
EP1914242A1
(fr)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Nouveau anticorps Anti-CD38 pour le traitement du cancer
|
DK2099823T4
(da)
|
2006-12-01 |
2022-05-09 |
Seagen Inc |
Målbindingsmiddelvarianter og anvendelser deraf
|
EP2144628B1
(fr)
|
2007-05-08 |
2012-10-17 |
Genentech, Inc. |
Anticorps anti-muc16 produits avec de la cystéine et conjugués anticorps-médicament
|
DK2019104T3
(da)
|
2007-07-19 |
2013-12-16 |
Sanofi Sa |
Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
|
MY188455A
(en)
|
2007-10-19 |
2021-12-09 |
Genentech Inc |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
CA2718942A1
(fr)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Conjugues auristatine-lieur de medicament
|
GB0813432D0
(en)
|
2008-07-22 |
2008-08-27 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
CN102176873A
(zh)
|
2008-10-15 |
2011-09-07 |
捷迈有限公司 |
髓内钉
|
GB0819097D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
GB0819095D0
(en)
|
2008-10-17 |
2008-11-26 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
NZ594177A
(en)
|
2009-02-05 |
2014-02-28 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
CA2753158A1
(fr)
*
|
2009-02-23 |
2010-08-26 |
Glenmark Pharmaceuticals S.A. |
Anticorps humanises qui se fixent au cd19 et leurs utilisations
|
FR2949469A1
(fr)
|
2009-08-25 |
2011-03-04 |
Sanofi Aventis |
Derives anticancereux, leur preparation et leur application en therapeutique
|
JP2013503607A
(ja)
*
|
2009-09-01 |
2013-02-04 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリンおよびその使用
|
CA2775350A1
(fr)
|
2009-09-24 |
2011-03-31 |
Seattle Genetics, Inc. |
Conjugues ligand-medicament dr5
|
ES2449379T3
(es)
|
2010-02-09 |
2014-03-19 |
Bristol-Myers Squibb Company |
Derivados de bencilpirrolidinona como moduladores de la actividad de receptores de quimiocinas
|
WO2011130615A2
(fr)
|
2010-04-15 |
2011-10-20 |
Dr. Reddy's Laboratories Ltd. |
Synthèse de lacosamide
|
SI2528625T1
(sl)
|
2010-04-15 |
2013-11-29 |
Spirogen Sarl |
Pirolobenzodiazepini in njihovi konjugati
|
CA2795353C
(fr)
|
2010-04-15 |
2018-01-09 |
Spirogen Developments Sarl |
Pyrrolobenzodiazepines utilisees pour traiter des maladies proliferatives
|
GB201006340D0
(en)
|
2010-04-15 |
2010-06-02 |
Spirogen Ltd |
Synthesis method and intermediates
|
AU2011239522B2
(en)
*
|
2010-04-15 |
2014-10-23 |
Medimmune Limited |
Targeted pyrrolobenzodiazapine conjugates
|
US9353127B2
(en)
|
2011-02-15 |
2016-05-31 |
Immunogen, Inc. |
Methods of preparation of conjugates
|
BR112014006703A8
(pt)
|
2011-09-20 |
2018-01-09 |
Spirogen Sarl |
"pirrolobenzodiazepinas
|
KR101877598B1
(ko)
|
2011-10-14 |
2018-07-11 |
메디뮨 리미티드 |
피롤로벤조디아제핀 및 그의 컨주게이트
|
EP2755642B1
(fr)
|
2011-10-14 |
2018-07-18 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazépines et conjugués ciblés
|
EA027386B1
(ru)
|
2011-10-14 |
2017-07-31 |
Медимьюн Лимитед |
Пирролобензодиазепины
|
KR101961976B1
(ko)
|
2011-10-14 |
2019-03-25 |
시애틀 지네틱스, 인크. |
피롤로벤조디아제핀 및 표적 접합체
|
JP6166728B2
(ja)
|
2011-10-14 |
2017-07-19 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
|
MX341523B
(es)
|
2011-10-14 |
2016-08-24 |
Medimmune Ltd |
Pirrolobenzodiazepinas.
|
AU2013255612B2
(en)
|
2012-04-30 |
2017-06-22 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
EP2855482B1
(fr)
|
2012-04-30 |
2017-03-01 |
MedImmune Limited |
Pyrrolobenzodiazépines
|
MX2015000357A
(es)
|
2012-07-09 |
2015-05-12 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd22.
|
MA37840B1
(fr)
|
2012-07-09 |
2020-05-29 |
Genentech Inc |
Immunoconjugués comprenant des anticorps anti-cd79b
|
JP2015528818A
(ja)
|
2012-08-02 |
2015-10-01 |
ジェネンテック, インコーポレイテッド |
抗etbr抗体およびイムノコンジュゲート
|
EP2906298B1
(fr)
*
|
2012-10-12 |
2018-10-03 |
ADC Therapeutics SA |
Conjugués pyrrolobenzodiazépine-anticorps
|
DK2906248T3
(en)
|
2012-10-12 |
2019-03-04 |
Medimmune Ltd |
Pyrrolobenzodiazepines and their conjugates
|
EP2906249B1
(fr)
|
2012-10-12 |
2018-06-27 |
MedImmune Limited |
Synthèse et intermédiaires de dérivés de pyrrolobenzodiazépine pour conjugaison
|
RS58921B1
(sr)
|
2012-10-12 |
2019-08-30 |
Medimmune Ltd |
Pirolobenzodiazepini i njihovi konjugati
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2018229222A1
(fr)
*
|
2017-06-14 |
2018-12-20 |
Adc Therapeutics Sa |
Régimes posologiques pour l'administration d'un cam anti-cd19
|